alagebrium has been researched along with Ventricular Dysfunction, Left in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Degroof, RC; Hundley, WG; Kitzman, DW; Little, WC; O'Brien, TX; Zile, MR | 1 |
| Redfield, MM | 1 |
1 review(s) available for alagebrium and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Treating diastolic heart failure with AGE crosslink breakers: thinking outside the heart failure box.
Topics: Animals; Clinical Trials as Topic; Collagen; Drug Evaluation, Preclinical; Glycation End Products, Advanced; Heart Failure; Humans; Thiazoles; Ventricular Dysfunction, Left | 2005 |
1 trial(s) available for alagebrium and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure.
Topics: Aged; Aorta; Blood Flow Velocity; Blood Pressure; Echocardiography; Exercise Test; Female; Glycation End Products, Advanced; Heart Failure; Humans; Magnetic Resonance Imaging; Male; Oxygen Consumption; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Ventricular Dysfunction, Left | 2005 |